These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20642501)

  • 21. The labeling and classification of chemical substances and preparations in the European community.
    Smeets J
    Regul Toxicol Pharmacol; 1983 Jun; 3(2):101-9. PubMed ID: 6612006
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prices of pharmaceutical preparations in Denmark until 1645: a study of the legislation for stipulating the consumer price of drugs].
    Kruse PR
    Theriaca; 1991 Oct; 27():3-315. PubMed ID: 11640853
    [No Abstract]   [Full Text] [Related]  

  • 23. A transition category of drugs: win-win-win-win?
    Marshall RP
    Am Pharm; 1992 Oct; NS32(10):64-7. PubMed ID: 1442533
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmaceutic economy and socialist organization science. 2. Problems of export market preparation].
    Onken D; Heublein D
    Pharm Prax; 1972; 2():Suppl 2:25-8. PubMed ID: 5037530
    [No Abstract]   [Full Text] [Related]  

  • 26. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 27. Product licence applications.
    Wolff F
    BMJ; 1991 Mar; 302(6778):729. PubMed ID: 2021756
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug safety through drug legislation].
    Kimbel KH
    Internist (Berl); 1978 Jun; 19(6):326-32. PubMed ID: 352981
    [No Abstract]   [Full Text] [Related]  

  • 29. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 30. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries].
    Burow W; Lüllmann H
    Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578
    [No Abstract]   [Full Text] [Related]  

  • 31. [Liability for drug-related damage by the pharmaceutical industry and the physician].
    Dahse G
    Beitr Gerichtl Med; 1982; 40():21-2. PubMed ID: 7165639
    [No Abstract]   [Full Text] [Related]  

  • 32. [On the project of legislation relative to drug trials "without medical intent"].
    Bastin R
    Bull Acad Natl Med; 1985 Jun; 169(6):881-4. PubMed ID: 3910188
    [No Abstract]   [Full Text] [Related]  

  • 33. [Guidelines for the certification of drug preparations according to the proposed new drug law].
    Rieger HJ
    Dtsch Med Wochenschr; 1976 Feb; 101(7):260-2. PubMed ID: 1248410
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 35. Extra-label drug use--pharmaceutical industry view.
    Welser JR
    J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug registration application in China.
    Zhen LH
    J Pharm Pharm Sci; 2003; 6(2):211-4. PubMed ID: 12935432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [European legislation on biological similarity recommendations of the European Agency on Medications concerning drug quality].
    Prugnaud JL
    Nephrol Ther; 2009 Feb; 5 Spec No1():3-5. PubMed ID: 19233075
    [No Abstract]   [Full Text] [Related]  

  • 38. [Problems in pharmaceutical preparations of acute poisoning antagonist--consideration from result of a questionnaire survey about pharmaceutical preparations].
    Hara C; Hashizume T; Tanaka J; Kirimitsu M; Onaka A; Kishimoto M; Matsuzaka M; Toma M; Shiono S; Tafuse H; Oishi M; Kurokawa N
    Chudoku Kenkyu; 2006 Jan; 19(1):57-9. PubMed ID: 16491883
    [No Abstract]   [Full Text] [Related]  

  • 39. Suggestion for a study on the implications of various chemicals and non-disease specific drugs.
    Beaconsfield P; Rainsbury R; Huxley J; Peters R; Tréfouël J; Monod J; Paul R; Theorell H
    Experientia; 1971 Jun; 27(6):715-7. PubMed ID: 5559835
    [No Abstract]   [Full Text] [Related]  

  • 40. Veterinary drug availability.
    Gloyd J
    J Am Vet Med Assoc; 1980 Apr; 176(7):611-4. PubMed ID: 7372533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.